Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Source: 
BioSpace
snippet: 

How exactly will health systems pay for these powerful yet ultra-expensive therapies? The list price on Kymriah, for instance, sits at $373,000 for its diffuse large B cell lymphoma indication and $475,000 for its acute lymphoblastic leukemia indication.